Physician profile
Jack W Lam
NPI 1578721395
$2,078.67
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $49.75 · 2021: $560 · 2022: $636 · 2023: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $201.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $755.54 | 2019-2022 | |
| Spr Therapeutics, INC | $347.87 | 2022 | |
| Genentech USA, INC. | $277.04 | 2019 | |
| Collegium Pharmaceutical, INC. | $223.60 | 2020-2023 | Belbuca, Xtampza |
| Vertos Medical, INC. | $89.19 | 2019-2022 | |
| Nevro Corp. | $56.16 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $55.14 | 2019-2023 | Ztlido |
| Grt US Holding, INC. | $48.46 | 2022 | |
| Si-Bone, INC. | $44.90 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.65 | 2022 | |
| Pfizer INC. | $27.90 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.43 | 2022 | |
| Tersera Therapeutics LLC | $19.39 | 2022 | |
| Boston Scientific Corporation | $18.40 | 2021 | |
| Forte Bio-Pharma LLC | $17.76 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.88 | 2023 | |
| Sentynl Therapeutics, INC. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.